Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

June 28, 2018

Study Completion Date

July 27, 2018

Conditions

Epidermolysis BullosaPruritus

Interventions

DRUG

VPD-737

VPD-737 inhibits the receptor neurokinin-1.

OTHER

Placebo

Matching tablets to VPD-737 tablets without active drug

Trial Locations (1)

Stanford, Stanford

All Listed Sponsors

collaborator

Epidermolysis Bullosa Research Partnership

OTHER_GOV

collaborator

Vyne Therapeutics Inc.

INDUSTRY

lead

Jean Yuh Tang

OTHER

NCT02654483 - Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients | Biotech Hunter | Biotech Hunter